Key result
Irbesartan 150 mg daily significantly reduced systolic blood pressure by an average of 20.2 mmHg and was associated with a high persistence rate of over 80% at 4 months.
Why the study?
Does irbesartan improve blood pressure and treatment persistence in hypertensive patients?
Population
4,769 previously untreated or uncontrolled pre-treated hypertensive patients in Switzerland
Design
Cohort
Follow-up
up to 6 months (average slightly exceeding 4 months)
Authors
Loading...
May inform real-world persistence strategies in hypertension; leaves open whether factors predict outcomes in broader populations.
Observational (n=4,769)
Open-label
Yes
Does irbesartan improve blood pressure and treatment persistence in hypertensive patients?
Mean Difference: -20.2 (95% CI -20.7–-19.6)
p-value: p=<0.001
Irbesartan is effective and well-tolerated in a real-world hypertensive population, with early blood pressure control and good tolerability predicting treatment persistence.
Burnier et al. (2005) conducted an observational in Hypertension (n=4,769). Irbesartan was evaluated on Reduction in systolic blood pressure from baseline (MD -20.2 mmHg, 95% CI -20.7 to -19.6, p=<0.001). Irbesartan 150 mg daily significantly reduced systolic blood pressure by an average of 20.2 mmHg and was associated with a high persistence rate of over 80% at 4 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: